{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:43:15Z","timestamp":1790980995235,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,5,20]],"date-time":"2010-05-20T00:00:00Z","timestamp":1274313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>This prospective Phase II study is the first to assess the feasibility and efficacy of maintenance 5\u2010azacytidine for older patients with high\u2010risk myelodysplastic syndrome (MDS), chronic myelomonocytic leukaemia and MDS\u2010acute myeloid leukaemia syndromes in complete remission (CR) after induction chemotherapy. Sixty patients were enrolled and treated by standard induction chemotherapy. Patients that reached CR started maintenance therapy with subcutaneous azacytidine, 5\/28\u2003d until relapse. Promoter\u2010methylation status of <jats:italic>CDKN2B<\/jats:italic> (<jats:italic>P15 ink4b<\/jats:italic>), <jats:italic>CDH1<\/jats:italic> and <jats:italic>HIC1<\/jats:italic> was examined pre\u2010induction, in CR and 6, 12 and 24\u2003months post CR. Twenty\u2010four (40%) patients achieved CR after induction chemotherapy and 23 started maintenance treatment with azacytidine. Median CR duration was 13\u00b75\u2003months, &gt;24\u2003months in 17% of the patients, and 18\u201330\u00b75\u2003months in the four patients with trisomy 8. CR duration was not associated with <jats:italic>CDKN2B<\/jats:italic> methylation status or karyotype. Median overall survival was 20\u2003months. Hypermethylation of <jats:italic>CDH1<\/jats:italic> was significantly associated with low CR rate, early relapse, and short overall survival (<jats:italic>P<\/jats:italic>\u2003=\u20030\u00b7003). 5\u2010azacytidine treatment, at a dose of 60\u2003mg\/m<jats:sup>2<\/jats:sup> was well tolerated. Grade III\u2010IV thrombocytopenia and neutropenia occurred after 9\u00b75 and 30% of the cycles, respectively, while haemoglobin levels increased during treatment. 5\u2010azacytidine treatment is safe, feasible and may be of benefit in a subset of patients.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2010.08235.x","type":"journal-article","created":{"date-parts":[[2010,5,22]],"date-time":"2010-05-22T07:40:04Z","timestamp":1274514004000},"page":"293-302","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Maintenance treatment with azacytidine for patients with high\u2010risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy"],"prefix":"10.1111","volume":"150","author":[{"given":"Michael","family":"Gr\u00f6vdal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasheed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anni","family":"Aggerholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar","family":"Antunovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Astermark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Bernell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena\u2010Maria","family":"Engstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Kjeldsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olle","family":"Linder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette S.","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon M.","family":"Tangen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Wallvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"\u00d6berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hokland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sten E.","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Porwit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hellstr\u00f6m\u2010Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,7,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2005.00559.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-1681"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0354"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.08.008"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403054"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2144\/97222rr01"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V100.8.2957"},{"key":"e_1_2_7_9_1","first-page":"3853","article-title":"Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS","volume":"90","author":"De Witte T.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra072067"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050005"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1867"},{"key":"e_1_2_7_14_1","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating the prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg P.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2008.00325.x"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1193"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404019"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403035"},{"key":"e_1_2_7_19_1","first-page":"498","article-title":"Intensive chemotherapy with idarubicine, cytarabine, etoposide and G\u2010CSF priming in patients with advanced myelodysplastic syndrome ahd high\u2010risk acute myeloid leukemia","volume":"83","author":"Hofmann W.K.","year":"2007","journal-title":"Annals of Hematology"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3872"},{"key":"e_1_2_7_21_1","volume-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoitetic and Lymphoid Tissues","author":"Jaffe E.S.","year":"2001"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21723"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21699"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.45.1718"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2007.10.002"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0245"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.08.009"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2001.02933.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404940"},{"key":"e_1_2_7_30_1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1182\/blood-2001-12-0188","article-title":"Involvement and functional impairment of the CD34+ CD38\u2010 hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8","volume":"100","author":"Nilsson L.","year":"2002","journal-title":"Blood"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.11.1981"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.2147\/tcrm.2006.2.4.377"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-210393"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403552"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.117"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.12.4059"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02496.x"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2007.314"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.2973114.x"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401387"},{"key":"e_1_2_7_41_1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000484740","article-title":"A single\u2010tube PCR\u2010test for the diagnosis of Angelman and Prader\u2010Willi syndrome based on allelic methylation differences at the SNRPN locus","volume":"5","author":"Zeschnigk M.","year":"1997","journal-title":"European Journal of Human Genetics"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2010.08235.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2010.08235.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T04:41:37Z","timestamp":1697431297000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2010.08235.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,12]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1111\/j.1365-2141.2010.08235.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08235.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,12]]},"assertion":[{"value":"2010-07-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}